<DOC>
	<DOCNO>NCT00191074</DOCNO>
	<brief_summary>After approval amendment ( g ) , patient still receive study drug time schedule study visit . In addition , patient discontinue early core , blind phase study contact . All patient offer opportunity enter unblinded extension phase ( meet eligibility criterion ) continue somatropin treatment ( regardless initial treatment randomization ) reach final height .</brief_summary>
	<brief_title>Amendment ( g ) Unblinded Extension Phase Somatropin Patients With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Participation core , blind phase ability contact investigator . For patient treatment time amendment ( g ) , growth velocity great equal 1.5 cm/year measure prior 12month period . For patient choose discontinue treatment core , blind phase , bone age less equal 16 year boys less equal 14 year girls . Diabetes mellitus . History , evidence sign active malignancy within 5 year prior start extension phase . Any condition medication , opinion investigator , might significantly increase risk decrease efficacy growth hormone therapy .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>